-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Names & News
-
IASLC Recommendations Define Core Standards for Molecular Tumor Boards
Lead author, Dr. Mihaela Aldea, discusses how the IASLC’s recently published consensus statement could strengthen new and established molecular tumor boards.
-
Looking Ahead to the IASLC | ASCO 2025 North America Conference on Lung Cancer
Conference Chair Dr. Christine Bestvina shares what attendees can look forward to at this year’s must-attend event in Chicago.
-
IASLC Launches Beta Version of VIKTOR
The Basic and Translational Science Committee’s new tool aims to unify available digital knowledge about preclinical models into one accessible, reliable system.
-
IASLC Spotlight: Rare Tumors Committee
Committee Chair Dr. Paul Baas explains how the Rare Tumors Committee unites global experts and resources to advance progress in the field of rare thoracic malignancies.
-
IASLC Committee Spotlight: Multidisciplinary Clinical Science Committee
Dr. Tom Stinchcombe discusses how this new IASLC committee is aiming to define multidisciplinary care, improve global access, and support collaborative science.
-
Patient Perspective: Copay Accumulators Create Yet Another Cost Burden Faced by US Patients in Treatment with Targeted Therapies
Advocate and best-selling author Annabelle Gurwitch shines light on pharmacy benefit practices that cost patients thousands while increasing profits for insurance companies.
-
Global Insights into Smoking Cessation in Lung Cancer Screening
Drs. Rachael Murray and Emma O’Dowd say despite increasing evidence that cessation efforts within screening programs are effective, a lack of clear guidance means this opportunity is often missed.
-
Overcoming Resistance Remains a Challenge in Targeting KRAS
Dana-Farber’s Dr. Alice Shaw recently explored various combination strategies that show promise in preventing or delaying resistance in this previously undruggable space.
-
Pathology Researcher Keith Kerr Receives 2025 Heine H. Hansen Award
During his award lecture at the European Lung Cancer Congress, Dr. Kerr said lung cancer treatment has benefited from the bridging of the historical divide between pathology and medical oncology.
-
Combination Therapies as Frontline Treatment for EGFR-Mutated NSCLC: Are the Rewards Worth the Risks?
During a TTLC debate, Drs. Helena Yu and Shirish Gadgeel weighed the pros and limitations of osimertinib monotherapy and combination therapies.